We're making the next batch
Ships in ~7 days or less
These products are for laboratory research only and not intended for medical use. They must be handled by qualified professionals in controlled laboratory environments. This compound has not been evaluated by the FDA and is not approved for human or veterinary use.
Published preclinical research has primarily utilized Wistar and Sprague-Dawley rat models as well as mouse strains in behavioral assays (elevated plus-maze, open-field, learned helplessness paradigms), alongside ex vivo gene expression studies in hippocampal and cortical tissue. In vitro cytokine and immune cell assays have also been employed. Researchers are directed to the primary literature for detailed model-specific methodologies.
No. Selank supplied here is strictly for laboratory research and preclinical experimental use only. It is not approved by the FDA, EMA, or any equivalent regulatory authority as a therapeutic agent. It is not intended for administration to humans or for use in clinical, veterinary, or consumer applications.
Current research has focused on Selank's interactions with GABA-A receptor complexes and benzodiazepine binding sites, BDNF/TrkB neurotrophin signaling pathways, enkephalin-degrading enzymes (leucine and methionine enkephalin catabolism), and cytokine regulatory networks including IL-6, TNF-α, and interferon systems. These targets are being explored in preclinical and in vitro contexts to characterize its mechanism of action.
Quality controlled from start to finish. No outsourcing.
Selank is a synthetic heptapeptide analog of tuftsin with an added Pro-Gly-Pro sequence for stability. Supplied as a research reagent for in vitro laboratory assays only; not for human or animal use.
These references are provided for research purposes only. Citations do not imply endorsement or approval of this product for any specific application.
